Advances and Challenges in the Use of Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) for HIV
With continuous progress in HIV treatment, the mortality rate has significantly decreased, and new infections have stabilized. However, there is still a gap from the 2020 targets set by the United Nations Programme on HIV/AIDS. To control new HIV infections, a comprehensive use of behavioral and biomedical methods, including antiviral drugs for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), is crucial. This strategy aims to reduce HIV transmission and control new infections. The 19th European AIDS Conference (EACS 2023) was held in Warsaw, Poland, from October 18 to 20, 2023. At the conference, Professor Jean-Michel Molina from the University of Paris City, Saint Louis and Lariboisière Hospital, shared insights on the application and challenges of HIV PrEP and PEP.